Patients with mild chronic heart failure who are treated early on with the beta blocker carvedilol (Coreg) along with the angiotensin-converting enzyme (ACE) inhibitor enalapril demonstrated a significantly greater improvement in left ventricular remodeling than patients receiving either drug alone, according to a 572-patient study presented at the European Society of Cardiology (ESC) Congress in September in Berlin. The results reinforce current treatment recommendations.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

From the ESC Congress: Combination therapy improves LV remodeling in CHF better than monotherapy

Newsletter